Aliskiren/hydrochlorothiazide
| Combination of | |
|---|---|
| Aliskiren | Renin inhibitor |
| Hydrochlorothiazide | Diuretic |
| Clinical data | |
| Trade names | Tekturna HCT, Rasilez HCT, others |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Aliskiren/hydrochlorothiazide, sold under the trade name Tekturna HCT among others, is a fixed-dose combination medication for the treatment of hypertension (high blood pressure).[1][2] It contains aliskiren and hydrochlorothiazide.[1][2]
Aliskiren/hydrochlorothiazide was approved for medical use in the United States in January 2008,[3] and for use in the European Union in January 2009.[2]
References
- ^ a b c "Tekturna HCT- aliskiren hemifumarate and hydrochlorothiazide tablet, film coated". DailyMed. 7 January 2020. Retrieved 26 August 2020.
- ^ a b c d "Rasilez HCT EPAR". European Medicines Agency. Retrieved 27 August 2020.
- ^ "Drug Approval Package: Tekturna HCT (aliskiren/hydrochlorothiazide) NDA #022107". accessdata.fda.gov. 24 December 1999. Retrieved 27 August 2020.
{{cite web}}: Unknown parameter|lay-url=ignored (help)
External links
- "Aliskiren hemifumarate mixture with hydrochlorothiazide". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |